Literature DB >> 19223498

NRH:quinone oxidoreductase 2-deficient mice are highly susceptible to radiation-induced B-cell lymphomas.

Karim Iskander1, Roberto J Barrios, Anil K Jaiswal.   

Abstract

PURPOSE: NRH:quinone oxidoreductase 2 (NQO2) is known to protect against myelogenous hyperplasia. However, the role of NQO2 in prevention of hematologic malignancies remains unknown. Present studies investigated in vivo role of NQO2 in prevention of myeloproliferative disease and lymphomas. EXPERIMENTAL
DESIGN: Wild-type and NQO2-null mice were exposed to 0, 1, and 3 Gy gamma-radiation. One year later, the mice were analyzed for the development of myeloproliferative disease and lymphomas. Immunohistochemistry analysis determined the B- and T-cell origin of lymphomas. The mice were also sacrificed at 6 and 48 h after radiation exposure and bone marrow was collected and analyzed for p53, Bax, and B-cell apoptosis. Bone marrow cells were cultured and the rate of degradation of p53 was analyzed.
RESULTS: Seventy-two percent NQO2-null mice showed development of B-cell lymphomas in multiple tissues compared with 11% in wild-type mice exposed to 3 Gy gamma-radiation. In contrast, only 22% NQO2-null mice showed myeloproliferation compared with none in wild-type mice. Further analysis revealed that bone marrow from NQO2-null mice contained lower levels of p53 compared with wild-type mice due to rapid degradation of p53. In addition, the exposure to radiation resulted in lower induction of p53 and Bax and decreased B-cell apoptosis in NQO2-null mice.
CONCLUSION: NQO2-null mice are highly susceptible to develop radiation-induced B-cell lymphomas. The lack of significant induction of p53 and Bax and decrease in B-cell apoptosis presumably contributed to the development of lymphomas. NQO2 functions as endogenous factor in prevention against radiation-induced B-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223498      PMCID: PMC3118578          DOI: 10.1158/1078-0432.CCR-08-1783

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

Review 1.  Regulation of antioxidant response element-dependent induction of detoxifying enzyme synthesis.

Authors:  Anil K Jaiswal
Journal:  Methods Enzymol       Date:  2004       Impact factor: 1.600

Review 2.  NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms.

Authors:  D Ross; J K Kepa; S L Winski; H D Beall; A Anwar; D Siegel
Journal:  Chem Biol Interact       Date:  2000-12-01       Impact factor: 5.192

3.  An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2.

Authors:  S Harada; C Fujii; A Hayashi; N Ohkoshi
Journal:  Biochem Biophys Res Commun       Date:  2001-11-09       Impact factor: 3.575

4.  Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia.

Authors:  Delwin J Long; Amos Gaikwad; Asha Multani; Sen Pathak; Charles A Montgomery; Frank J Gonzalez; Anil K Jaiswal
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

5.  Crystal structure of human quinone reductase type 2, a metalloflavoprotein.

Authors:  C E Foster; M A Bianchet; P Talalay; Q Zhao; L M Amzel
Journal:  Biochemistry       Date:  1999-08-03       Impact factor: 3.162

6.  NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin.

Authors:  D J Long; R L Waikel; X J Wang; D R Roop; A K Jaiswal
Journal:  J Natl Cancer Inst       Date:  2001-08-01       Impact factor: 13.506

7.  NQO1 stabilizes p53 through a distinct pathway.

Authors:  Gad Asher; Joseph Lotem; Rachel Kama; Leo Sachs; Yosef Shaul
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

8.  Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.

Authors:  R J Knox; T C Jenkins; S M Hobbs; S Chen; R G Melton; P J Burke
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

9.  Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity.

Authors:  Delwin J Long; Karim Iskander; Amos Gaikwad; Meral Arin; Dennis R Roop; Richard Knox; Roberto Barrios; Anil K Jaiswal
Journal:  J Biol Chem       Date:  2002-09-25       Impact factor: 5.157

10.  NQO2 gene is associated with clozapine-induced agranulocytosis.

Authors:  O Ostrousky; S Meged; R Loewenthal; A Valevski; A Weizman; H Carp; E Gazit
Journal:  Tissue Antigens       Date:  2003-12
View more
  7 in total

Review 1.  Regulation of Nrf2-an update.

Authors:  Suryakant K Niture; Raju Khatri; Anil K Jaiswal
Journal:  Free Radic Biol Med       Date:  2013-02-19       Impact factor: 7.376

2.  Retraction: NRH:Quinone Oxidoreductase 2-Deficient Mice Are Highly Susceptible to Radiation-induced B-Cell Lymphomas.

Authors:  Karim Iskander; Roberto J Barrios; Anil K Jaiswal
Journal:  Clin Cancer Res       Date:  2018-11-01       Impact factor: 12.531

Review 3.  Resveratrol: Biological and pharmaceutical properties as anticancer molecule.

Authors:  Tze-chen Hsieh; Joseph M Wu
Journal:  Biofactors       Date:  2010 Sep-Oct       Impact factor: 6.113

4.  Role of NQO1 609C>T and NQO2 -3423G>A gene polymorphisms in esophageal cancer risk in Kashmir valley and meta analysis.

Authors:  Manzoor Ahmad Malik; Showkat Ali Zargar; Balraj Mittal
Journal:  Mol Biol Rep       Date:  2012-06-27       Impact factor: 2.316

5.  NRH:quinone oxidoreductase 2 (NQO2) protein competes with the 20 S proteasome to stabilize transcription factor CCAAT enhancer-binding protein α (C/EBPα), leading to protection against γ radiation-induced myeloproliferative disease.

Authors:  Junkang Xu; Brad Allen Patrick; Anil K Jaiswal
Journal:  J Biol Chem       Date:  2013-10-19       Impact factor: 5.157

6.  Genome-wide analysis of long noncoding RNA (lncRNA) expression in colorectal cancer tissues from patients with liver metastasis.

Authors:  Dong Chen; Qiang Sun; Xiaofei Cheng; Lufei Zhang; Wei Song; Dongkai Zhou; Jianjiang Lin; Weilin Wang
Journal:  Cancer Med       Date:  2016-05-11       Impact factor: 4.452

7.  NAD(P)H: quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 polymorphisms in papillary thyroid microcarcinoma: correlation with phenotype.

Authors:  Junguee Lee; Koon Soon Kim; Min Ho Lee; Yeon Soo Kim; Min Hee Lee; Seong Eun Lee; Yong Kyung Kim; Min Jeong Ryu; Soung Jung Kim; Min Jeong Choi; Young Suk Jo
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.